NBIX Biotechnology / Pharmaceutical Pre-earnings LONG

2月7日

Neurocrine Biosciences, a mid cap pharmaceutical firm is up for earnings on February 7th.

Investor and trader interest seems to be moderately increasing in the past week. The combined

MACD / RSI indicator is bullish. This looks good for a longtrade to be taken in the premarket

before 7:45 AM as earnings report at 8:00

2月7日

交易开始

prnewswire.com/news-releases/neurocrine-biosciences-reports-fourth-quarter-and-fiscal-2023-financial-results-and-provides-financial-expectations-for-2024-302055386.html

The earnings report was decent but perhaps lower than trader expectations.

I expect the dip is a good entry point for an add of position.

2月7日

交易开始

Half of the shares @ 144 and the second half @ 137 for an average of 140.5 currently
a small loss with bullish momentum as traders realize that a 20% earnings beat with flat revenue means that belt trimming has occurred which provides context to
forward guidance.

2月10日

交易开始

The tourniquet did not help (LOL, IMO); I am a believer I will hold out; big wins elsewhere today. patience abounding but no more adds. Will wait for the attention for tech earnings to evaporate and see if the recovery happens.